#cvHCM is the most common genetic heart disease in the U.S. Help your patients make informed decisions by reviewing treatment options, goals, and next steps.

Share #CardioSmart resources to guide the conversation. ➡️ https://bit.ly/3ZRXmAV

#HeartMonth #HCMAwarenessDay #CardioSky #MedSky

ACC/AHA/Multisociety released an updated #cvHCM guideline in 2024, with evidence-based recommendations that build on those from the 2020 #HCM Guideline.

Explore the Guideline-at-a-Glance: bit.ly/4gYhveD

#JACC #MedSky #CardioSky @jaccjournals.bsky.social

🎥 #ACCAnywhere TV From #ESCCongress 2025 Quick Takes: Dr. Milind Y. Desai shares key takeaways from the ODYSSEY-HCM trial, a study of mavacamten in non-obstructive hypertrophic cardiomyopathy, with #JACC Associate Editor Dr. Michelle M. Kittleson.

More: https://bit.ly/3HT8FDt

#cvHCM #JACCJournals

Mavacamten did not 🚫 significantly improve exercise capacity or patient-reported health status vs. placebo in patients with symptomatic nonobstructive #cvHCM, according to ODYSSEY-HCM results presented at #ESCCongress. 🔗 https://bit.ly/41rNPlk #JACC @jaccjournals.bsky.social

Results from MAPLE-HCM at #ESCCongress found aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms among patients with symptomatic obstructive #cvHCM. Read more: https://bit.ly/3HK63rv

🫀 Did you know #cvHCM affects at least 1 in 500 adults? Help patients better understand HCM with free, evidence-based resources from #CardioSmart, including discussion guides, infographics and patient handouts.

Download today ➡️ https://bit.ly/4fhuyKC #CardioSky #MedSky

Learn the latest on the evaluation & management of #cvHCM in athletes as part of #ACCAthleticHeart, an ACC Anywhere video series from the #ACC26 pre-conference focused on the unique demands of #SportsCardio.

Watch on #ACCAnywhere 👉 https://bit.ly/4v9N789 #ACCSportsCardio

MAPLE-HCM: Patients with oHCM treated with aficamten saw superior benefits in #heartfailure symptoms, exercise capacity, LVOT gradient and overall health status when compared to metoprolol.

Learn more: https://bit.ly/47wIVqD

#AHA25 #JACC #HCM #cvHCM #CardioSky #MedSky @jaccjournals.bsky.social

ODYSSEY-HCM: Mavacamten shows no significant improvement in outcomes for patients with symptomatic nonobstructive #cvHCM. Drs. Matt Martinez and Milind Desai explore the findings and discuss future treatment of HCM on this episode of 🎧 ACCEL Lite: https://bit.ly/3WvEDZZ

#CardioSky #MedSky

🆕 ACC Launches HCM Digital Registry

The ACC aims to accelerate insights into #cvHCM & expand equitable access to treatment. CONNECT-HCM digital registry aims to ↗️ understanding & improve care for what is one of the most common genetic #CVDs. More: https://bit.ly/471eUiI

#CardioSky #MedSky